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Over the past decade, the research agenda in dialysis has
been dominated by studies on risk factors associated with
cardiovascular mortality. It has now become increasingly
clear that in dialysis patients, non-cardiovascular causes of
death are increased to the same extent as cardiovascular
mortality, and therefore research efforts in this area deserve
an equally prominent place on the nephrology research
agenda. As previous research has suggested an association
between cardiovascular disease and infections, more
research on potential links between the causal pathways
of cardiovascular events and infections is also warranted.
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More than a decade ago, Foley et al.1 had studied a USRDS
data set including patients with end-stage renal disease
(ESRD), and after stratification for age, race, and sex they
found mortality from cardiovascular disease to be 10–20 times
higher in ESRD patients compared with the general popula-
tion. This study has been cited more than 800 times, frequently
to justify studies pertaining to the effect of cardiovascular risk
factors on mortality in chronic kidney disease (CKD) patients.
Even more common, this reference has been used to underline
the fact that cardiovascular disease, which is responsible for
around half of the deaths in dialysis patients, is the most
important cause of death in this population. Finally, the
findings of the study by Foley et al. have not only been used to
justify specific studies, but they have also to a large extent set
the research agenda for CKD since their publication in 1998.
Although it has been established beyond any doubt that
cardiovascular events are an important cause of death in
CKD patients, this is only half the truth. Cardiovascular
mortality is also important in the general population.
Depending on the age category, it is responsible for
10–50% of mortality in the general population, whereas in
dialysis patients these percentages are 20–40.2 Therefore, the
fraction of cardiovascular deaths is quite similar in both
populations. From this perspective, the findings of Foley et al.
can only be understood if in dialysis patients mortality due to
non-cardiovascular disease is increased to the same extent as
mortality from cardiovascular causes. Indeed, results from
other studies conducted on the same USRDS data set have
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shown that, in dialysis patients, mortality from sepsis is
50 times higher3 and that from pulmonary infections is 14–16
times higher4 compared with the general population.
However, these findings have received very little attention
compared with those showing increased cardiovascular
mortality. More recently, de Jager et al.2 analyzed data from
the European Renal Association–European Dialysis and
Transplant Association (ERA–EDTA) Registry and not only
confirmed the findings of Foley and colleagues but also
showed that in dialysis patients mortality from non-
cardiovascular disease was increased to the same extent as
mortality from cardiovascular disease. Taking the general
population in Europe as a reference, the age-adjusted
cardiovascular mortality in dialysis patients was 8.8 times
higher, whereas the non-cardiovascular mortality was in-
creased 8.1 times.2 To add to this perspective, it is interesting
to note that the increased risk of both cardiovascular and
non-cardiovascular mortality in dialysis patients is comple-
mented by the observation that, in elderly individuals with a
more advanced stage of CKD, the age- and sex-adjusted risk
of death from non-cardiovascular causes is increased
compared with those with better renal function.5 Apparently,
individuals with CKD die prematurely from all kinds of
causes compared with individuals of the same age in the
general population. We recently presented clinical and
experimental data showing that the cardiovascular events
associated with atherosclerosis are more often fatal in
patients with CKD than in individuals without CKD.6
The studies on ERA–EDTA Registry and USRDS data in
dialysis patients2–4 are particularly worrisome, as their results
do not seem to fit well with the commonly held opinion
that, in order to reduce the highly increased mortality in these
patients, we should predominantly study and decrease
traditional and non-traditional cardiovascular risk
factors. On the other hand, from these studies it cannot be
concluded that investigating and treating cardiovascular
risk factors in CKD patients would not be helpful. We
would simply like to argue that reduction of cardiovascular
and non-cardiovascular mortality deserves equal attention.
Our understanding is further hampered by the publication
in the past few years of a number of ‘negative trials’,
randomized controlled trials (RCTs) that failed to show
a beneficial effect of interventions aimed at decreasing
cardiovascular risk factors, although such interventions have
established positive effects on mortality in the general
population. For instance, cardiovascular end points
including cardiovascular mortality were not reduced in
CKD or dialysis patients in published RCTs in which they
attempted to correct, for example, hypercholesterolemia7,8 or
anemia.9,10
Given these findings from epidemiological and interven-
tion studies, three questions arise:
(1) Why are both cardiovascular and non-cardiovascular
mortality rates increased to the same extent?
(2) What are the effects of cardiovascular disease on non-
cardiovascular events and vice versa? and
(3) Why does treatment of established cardiovascular risk
factors not seem to decrease cardiovascular mortality in
dialysis patients?
In relation to the first question, it is common knowledge
that non-cardiovascular causes of death, such as malignancy,
share a number of risk factors with cardiovascular mortality—
for example, smoking, obesity, physical inactivity, and
diet. The prevalence of some of those factors is increased in
CKD patients, as they are also risk factors for CKD itself.
On the contrary, cancer itself, as well as the adverse
effects of therapies for cancer, can directly or indirectly cause
CKD.11 Also related to the first question, both cardiovascular
and infectious causes of death are linked to inflammation
and it has become increasingly appreciated that ESRD is
characterized by a state of chronic inflammation.12 There is a
wealth of evidence indicating that disorders of both innate
and adaptive immune systems contribute to an increased
rate of infections in the course of ESRD.13 Although defensive
responses are impaired, the immune system is also under
constant stimulation because of the process of dialysis itself.14
With regard to the second question, it has been shown
that infections and cardiovascular events are interrelated. In
individuals under the care of a general practitioner, the risk
of myocardial infarction and that of stroke were substan-
tially higher after a diagnosis of systemic respiratory tract
infection, especially during the first 3 days of infection.15
This supports the concept that acute infections are associated
with a transient increase in the risk of vascular events.15
Furthermore, Ishani et al.16 showed that in dialysis patients
septicemia or bacteremia was associated with subsequent
death, myocardial infarction, heart failure, peripheral vas-
cular disease, and stroke. They concluded that septicemia
appears to be an important, potentially preventable, cardio-
vascular risk factor in this patient group. Conversely,
particular cardiovascular diseases such as heart failure and
volume overload may elicit conditions favorable for the
development of infections. In this context, it is interesting
that in ESRD patients volume overload is one of the putative
causes of elevated circulating TNF-a levels.14 Thus, infections
are associated with subsequent cardiovascular events, and
particular cardiovascular disorders may elicit infections. It is
possible that these problems may aggravate each other.
Therefore, other potential causal pathways in the link
between non-cardiovascular and cardiovascular diseases and
their potential common causes (including the role of the
immune system) also need to be studied further. Hypotheses
in this area need to be tested in animal models and laboratory
experiments.
An answer is also much needed for the third question.
RCTs in CKD to date have studied interventions that in the
general population have been shown primarily to reduce
death from myocardial infarction or stroke. However, in
dialysis patients, an important part of the cardiovascular
deaths can be attributed to other ‘‘competing’’ causes of
death,17 such as sudden death, which may not be modifiable
by interventions aimed to reduce hypercholesterolemia or
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anemia. In addition, dialysis patients comprise a highly
selected population.17 It is therefore possible that in these
RCTs interventions were tested that are relatively ineffective
in the reduction of total mortality in this particular patient
population. Studies on (addressing) risk factors for sudden
death are warranted.
In conclusion, the research agenda for the reduction of
mortality in dialysis patients (Figure 1) should focus on both
cardiovascular and non-cardiovascular causes of death. In
addition, research in cardiovascular mortality may better
differentiate between the effects of interventions aimed to
reduce specific types of cardiovascular mortality. Finally, the
potential link between cardiovascular and non-cardiovascular
mortality deserves further investigation.
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Figure 1 |Proposal for a new research agenda on the
cardiovascular–renal and non-cardiovascular–renal links.
1. To hypothesize and investigate potential mechanisms for
increased non-cardiovascular mortality in chronic kidney
disease (CKD)/dialysis patients, including infections and
malignancies.
2. To study the link between cardiovascular and
non-cardiovascular events and to investigate potential
common causes.
3. To test hypotheses in animal models and laboratory
experiments.
4. Thereafter, to study the effect of markers and modifiable
risk factors in carefully designed observational studies in the
CKD/dialysis population.
5. To test the effects of smart interventions in randomized
controlled trials.
6. To include risk factors for sudden death, and related potential
interventions, into the studies on cardiovascular mortality
in this population.
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